IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
23.15
+0.97 (4.37%)
Jan 21, 2025, 4:00 PM EST - Market closed
IDEAYA Biosciences Employees
IDEAYA Biosciences had 124 employees as of December 31, 2023. The number of employees increased by 21 or 20.39% compared to the previous year.
Employees
124
Change (1Y)
21
Growth (1Y)
20.39%
Revenue / Employee
$31,629
Profits / Employee
-$1,436,452
Market Cap
2.00B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
IDYA News
- 9 days ago - IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance - PRNewsWire
- 23 days ago - IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors - PRNewsWire
- 25 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 5 weeks ago - IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma - PRNewsWire
- 5 weeks ago - IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers - PRNewsWire
- 5 weeks ago - IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 - PRNewsWire
- 6 weeks ago - IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer - PRNewsWire
- 6 weeks ago - IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor - PRNewsWire